Careers in Israel
Careers in the US
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Annual and Quarterly Reports
pioneer in computational drug target discovery
Innovative immuno-oncology pipeline
Jun 01, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb’s Opdivo® (Nivolumab) and TIGIT Inhibitor
May 27, 2020
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
Research and Development
Our optimized process for predictive discovery of novel drug targets
Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target
Compugen, FROM CODE TO CURE®(video)
COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint target candidate discovered computationally by Compugen.
BAY 1905254/ILDR2 (partnered)
ILDR2 (formerly CGEN-15001T) is a novel immune checkpoint target discovered by Compugen and partnered to Bayer.
COM902, an anti-TIGIT inhibitor, is being developed as an integral component of the COM701 program, to facilitate the combination strategy for COM701.
COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701
Multiple myeloid programs
Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action.
May 06, 2020
Compugen First Quarter 2020 Conference Call
Apr 27, 2020
COM701 Demonstrates Preliminary Antitumor Activity as Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Tumors (oral presentation)
2020 AACR Virtual Annual Meeting I
Feb 20, 2020
Compugen Fourth Quarter and Full Year 2019 Conference Call
Click here for more info about partnering with Compugen